$PIRS Analysis

/ / Day Trading, Stock Analysis

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. The company develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

The company primarily focuses on the development of three drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; and PRS-343, a bispecific protein for oncology diseases.

The company has collaboration agreements with Allergan, Inc.; Daiichi Sankyo Company Limited; Sanofi Group; Cadila Healthcare Limited (Zydus Cadila); Strides Arcolab Limited; and F.HoffmannLa Roche Ltd. It also has a strategic alliance with Servier Forge for the co-development of immuno-oncology. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

As of January 26th 2017, $PIRS looks to be bullish, for a 1 to 2 week hold. A purchase at a

price between $1.95 and $2.10 is safe and could bring you returns between 10% and

15% in the next 30 days. Be sure you place a stop loss at 10% below you buy price, and

don’t be greedy, a consistent 10% to 15% per month can help dealing with losses and

sometimes help bring in more profits.

 

Also please keep in mind we are not offer trading advice, we are just sharing an idea.

For real stock trading advice you should contact a professional financial adviser.

—————————————————————————————————————————————————————————————


These reviews are from our current members, you join us for a trial and access the chatroom to confirm if these reviews are in fact true.


You must be logged in to post a comment.